Custom Antibody Market by Type, Service, Source, Research Area, End Users, Application

Description

List of Tables

[188 Pages Report] The Custom Antibody Market size was estimated at USD 755.86 million in 2023 and expected to reach USD 871.88 million in 2024, at a CAGR 16.10% to reach USD 2,149.90 million by 2030.

Custom antibodies are specialized proteins designed and produced to bind specifically to a single target molecule, known as an antigen. These antibodies are tailor-made to recognize and bind with high specificity to unique sites on target molecules, making them valuable tools in research, diagnostic, and therapeutic applications. The custom production of antibodies allows researchers to generate specific reagents for novel or less-studied targets or to create antibodies with desired properties that are not available off the shelf. The high prevalence and incidences of chronic and infectious diseases worldwide necessitate the development of novel diagnostic and therapeutic antibodies. Heightened investment in research and development by biopharmaceutical companies and academic institutions boosts the proliferation of custom antibodies. However, the intricate processes involved in custom antibody production can be cost-intensive, and stringent regulatory requirements for antibody therapeutics can delay market entry and increase development costs. Moreover, generating antibodies with high specificity and affinity remains challenging, impacting the effectiveness of custom antibody applications. However, key players are exploring the integration of AI/ML algorithms and robotics technologies to ease the process of antibody discovery and design. Furthermore, the development of more efficient hybridoma technology and recombinant antibody production and expanding applications in targeted drug delivery systems and diagnostic imaging could also benefit the growth of the industry.

KEY MARKET STATISTICS
Base Year [2023]	USD 755.86 million
Estimated Year [2024]	USD 871.88 million
Forecast Year [2030]	USD 2,149.90 million
CAGR (%)	16.10%

Type: Emerging need for monoclonal antibodies to tackle severe disease states

Monoclonal antibodies are identical antibodies produced by a single B-cell clone. These antibodies are highly specific to a single epitope, making them valuable in research, diagnostic, and therapeutic contexts, particularly for the treatment of cancers, autoimmune diseases, and infectious diseases. They are chosen for their specificity and consistency in targeting a single antigen and are ideal in therapeutic contexts where targeting a specific molecular pathway is crucial. Polyclonal antibodies are derived from different immune cells and recognize multiple epitopes on an antigen. This makes them extremely versatile and widely used in research applications, particularly for detecting and purifying a wide variety of proteins. They are preferred for their ability to recognize multiple epitopes, enhancing sensitivity in diagnostic assays, and are particularly valuable in research settings for protein detection and analysis. Recombinant antibodies are engineered in vitro using recombinant DNA technology. This category includes single-domain antibodies and fragment antibodies. Their highly customizable nature makes them suitable for a broad range of applications, from research to therapeutic use. They are selected for applications requiring high specificity and reproducibility without the batch-to-batch variation seen in polyclonal antibodies and are suited for therapeutics and in vitro diagnostics.

End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics

Academic and research institutes significantly invest in basic and applied research projects that require custom antibodies to uncover novel insights into biological processes and disease mechanisms. Their preference leans towards highly specific, customizable options that can be used in various research settings, including proteomics and genomics studies. These entities value providers that offer technical support and competitive pricing due to budget constraints. Contract research organizations (CROs) serve as a bridge between pharmaceutical companies and research activities, conducting a wide array of clinical trials and research projects on behalf of their clients. Their need for custom antibodies revolves around high reproducibility, bulk orders, and time efficiency to meet project timelines and regulatory standards. Notably, CROs prefer vendors that can provide extensive documentation and validation services. Hospitals and clinics primarily utilize custom antibodies for diagnostic purposes and in personalized medicine applications. The demand within this sector is for highly accurate, clinically validated antibodies that can be used in diagnostics and patient monitoring. Suppliers that can offer robust support in clinical trial phases and regulatory approval processes are highly valued. Pharmaceutical and biotechnology companies represent a significant portion of the need for custom antibodies, mainly for drug discovery and development processes. These companies prioritize antibodies that can be integrated into high-throughput screenings, therapeutic applications, and as biomarkers in clinical trials. They seek vendors that are capable of providing large-scale, consistent quality products with thorough documentation and compliance with regulatory standards.

Regional Insights

The Americas, particularly the U.S. and Canada, are known for their robust research environments, contributing significantly to the demand for custom antibodies. The region's strong biotechnology and pharmaceutical sectors drive this need, with both academic and commercial labs seeking high-quality, specific antibodies for therapeutic and diagnostic applications. Recent patents in the U.S. indicate a focus on novel cancer biomarkers and neurodegenerative diseases, highlighting the ongoing innovation in antibody development. European Union (EU) countries boast advanced healthcare systems and strong regulatory support for biotechnology research, fostering a conducive environment for custom antibody development. The presence of stringent regulations for therapeutics and diagnostics molecules in the EU provides a standardized and secure framework for the progression of custom antibodies. Recent EU investments focus on combating infectious diseases and addressing chronic conditions, such as autoimmune disorders, through innovative antibody solutions. The APAC region has emerged as a pivotal landscape in the custom antibody market, supported by several government-funded initiatives to advance the healthcare infrastructure and provide marginalized communities access to diagnostics and therapeutic capabilities. China's focus on biotechnology innovation and government investments in genomics and proteomics research is creating a need for highly specialized antibodies. Japan's well-established pharmaceutical industry prioritizes precision medicine, and India's burgeoning biotechnology sector, coupled with its cost-effective manufacturing capabilities, has proved crucial for the growth of custom antibodies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Custom Antibody Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Custom Antibody Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Custom Antibody Market, highlighting leading vendors and their innovative profiles. These include Abbiotec, Inc., Abcam PLC, ABclonal, Inc., Abgenex Pvt. Ltd., Abnova Corporation, Acrobiosystems Inc., Agilent Technologies, Inc., Alta Bioscience Limited, Bio Basic Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioChain Incorporated, Bioklone Biotech Private Limited, BioLegend, Inc. by PerkinElmer, Inc., Biosynth Ltd., Boster Biological Technology, BTL Biotechno Labs Private Limited, Capralogics, Inc., Cell Signaling Technology, Inc., CiteAb Limited, Creative Biolabs, Creative Diagnostics, CSBio (Shanghai) Ltd., Cusabio Technology LLC, Davids Biotechnologie GmbH, Elabscience, evitria AG by Atlas Antibiodies, GenScript Biotech Corporation, Imgenex India Pvt. Ltd., Innovagen AB, Inotiv, Inc., Kaneka Eurogentec S.A., Laboratory Corporation of America Holdings, Merck KGaA, Metabion International AG, MyBiosource, Inc., OriGene Technologies, Inc., Oy Medix Biochemica AB, Pacific Immunology, PhosphoSolutions, ProMab Biotechnologies, Inc., ProSci Incorporated, ProteoGenix SA, RayBiotech Life, Inc., Rockland Immunochemicals, Inc., Sino Biological, Inc., The Antibody Company, Thermo Fisher Scientific, Inc., and YenZym Antibodies, LLC.

Market Segmentation & Coverage

This research report categorizes the Custom Antibody Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies

Service
- Antibody Development
- Antibody Fragmentation & Labeling
- Antibody Production & Purification

Source
- Mice
- Rabbit

Research Area
- Cardiovascular Diseases
- Immunology
- Infectious Diseases
- Neurobiology
- Oncology
- Stem cells

End Users
- Academic & Research Institutes
- Contract Research Organizations
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies

Application
- Research
- Therapeutics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Custom Antibody Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Custom Antibody Market?

3. What are the technology trends and regulatory frameworks in the Custom Antibody Market?

4. What is the market share of the leading vendors in the Custom Antibody Market?

5. Which modes and strategic moves are suitable for entering the Custom Antibody Market?

Product Code: MRR-46132FF79A8E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of chronic infectious disease worldwide
  - 5.1.1.2. Expanding applications of custom antibody across research, diagnostics, and therapeutics
  - 5.1.1.3. Rising adoption of advanced technologies in antibody engineering and personalized therapeutics
- 5.1.2. Restraints
  - 5.1.2.1. Extensive and time consuming to develop custom antibodies
- 5.1.3. Opportunities
  - 5.1.3.1. Governments and private sector strategically investments in life science and clinical research
  - 5.1.3.2. Increase in therapeutics of antibodies and expansion of drug pipeline
- 5.1.4. Challenges
  - 5.1.4.1. Presence of alternative antibodies
5.2. Market Segmentation Analysis
- 5.2.1. Type: Emerging need for monoclonal antibodies to tackle severe disease states
- 5.2.2. End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Custom Antibody Market, by Type

6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies
6.4. Recombinant Antibodies

7. Custom Antibody Market, by Service

7.1. Introduction
7.2. Antibody Development
7.3. Antibody Fragmentation & Labeling
7.4. Antibody Production & Purification

8. Custom Antibody Market, by Source

8.1. Introduction
8.2. Mice
8.3. Rabbit

9. Custom Antibody Market, by Research Area

9.1. Introduction
9.2. Cardiovascular Diseases
9.3. Immunology
9.4. Infectious Diseases
9.5. Neurobiology
9.6. Oncology
9.7. Stem cells

10. Custom Antibody Market, by End Users

10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Research Organizations
10.4. Hospitals & Clinics
10.5. Pharmaceutical & Biotechnology Companies

11. Custom Antibody Market, by Application

11.1. Introduction
11.2. Research
11.3. Therapeutics

12. Americas Custom Antibody Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Custom Antibody Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Custom Antibody Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Danaher to Buy Antibody Supplier Abcam for USD 5.7 Billion
- 15.3.2. Merck to Develop mAb Through USD 10.8 Billion Acquisition
- 15.3.3. Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies
15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

16.1. Key Company Profiles
16.2. Key Product Portfolio